CURRICULUM VITAE

James Whitfield Logan, MD, FACR

Appalachian Regional Internal Medicine Specialists

*** *** *** *********, ***** 104, Boone, NC 28607

828-***-****- Fax 828-***-****- cell 501-***-****

Email: adk3v5@r.postjobfree.com

Home address: 170 Clear SkyTrail, R2B, Banner Elk, NC 28604

Postgraduate Training

Fellowship: 1991-1993 Rheumatology. Tufts- New England Medical Center, Boston, MA

Residency: 1988-1990 Internal Medicine. University of Arkansas for Medical Sciences, Little Rock, AR

Internship: 1987-1988 Internal Medicine. University of Arkansas for Medical Sciences, Little Rock, AR

Education

1982-1987 MD, Louisiana State University Medical Center, Shreveport, LA

1978-1982 BS Zoology. Louisiana Tech University, Ruston, LA

Employment

2013- Present Appalachian Regional Internal Medicine Specialists, Boone, NC

2008-2013 St Joseph Mercy Medical Clinic, Hot Springs, AR

2002-2008 Heritage Medical Clinic, Hot Springs,AR

2000-2002 Arthritis Affiliates, PC, Colorado Springs, CO

1999-2000 Associate Professor of Medicine, Department of Rheumatology, University of Arkansas for Medical Sciences and John L McClellan VAMC, Little Rock, AR

1993-1999 Assistant Professor of Medicine, Department of Rheumatology, University of Arkansas for Medical Sciences and John L McClellan VAMC, Little Rock, AR

1990-1991 Staff physician, Fort Roots VAMC, North Little Rock, AR

Licensure

North Carolina 2013-01084

ABIM Internal Medicine 1994

ABIM Rheumatology 1996, recertification 2007, 2013

Memberships

American Board of Internal Medicine

Fellow American College of Rheumatology

North Carolina Medical Society

North Carolina Rheumatology Association

Research

Phase III, 12 Week, Multi-Center, Open-Label, Safety and Efficacy Study of Diclofenac Sodium in Adults Aged 18-80 with Rheumatoid Arthritis.

Humira Efficacy Response Optimization Study in Subjects with Active Rheumatoid Arthritis (HERO)

A Randomized, Double-blind, Double- dummy, Parallel Group Study of the Safety and Efficacy of MRA monotherapy, versus Methotrexate Monotherapy, in Patients with active Rheumatoid arthritis, WA18062

A 24 Week Randomized, Double-blind, Placebo controlled, Parallel Group Study of the Safety and Reduction of Signs and Symptoms during Treatment with MRA versus placebo, in Combination with Methotrexate in Patients with Moderate to Severe Active Rheumatoid Arthritis and an inadequate Response to anti TNF Therapy, WA18062

A Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of Euflexxa for Treatment of Painful Osteoarthritis of the Knee, with an Open-label Safety Extension.

Genentech-Roche WA20494/ACT3985g-A Phase III Program Investigating two dose regimens of Rituximab, Two infusions of Either 500 mg x 2 Separated by 14 Days Between Treatments is underway in patients with RA unresponsive to MTX and in patients with RA but Naive to MTX Treatment.

Genentech-Roche-Script WA20495/ACT3986g- A Randomized, Double-blind, Parallel Group, International Study to Evaluate the Safety and Efficacy or Ocrelizumab Compared to Placebo in Patients with Active RA who have an Inadequate Response to at Least one anti-TNF Therapy.

Bristol-Myers-Squib- IM101174- Randomized, Double-blind, Double-dummy Study to Compare the Efficacy and Safety of Abetacept Administered Subcutaneously and Intravenously in subjects with RA Receiving Background Methtrexate, and Experiencing an Inadequate Response to Methotrexate.

UCB-C87094-(REALISTIC)- A Phase III Randomized, Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase to Evaluate the Safety and Efficacy of Certolizumab Pegol Administered to Patients with Active RA.

Roche-ACT-Star ML22533- An Open label, Randomized Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab(TCZ) Monotherapy or TCZ in Combination with Non-biologic DMARDs in Patients with Active RA who Have an Inadequate Response to Current Non-biologic or Biologic DMARDs.

IMI101-235- Phase IIIB- A Randomized, Head go Head, Single-blind Study to Compare the Efficacy and Safety of Subcutaneous Abetacept versus Subcutaneous Abalimumab, Both with background Methotrexate in Biologic Naive Subjects with RA.

Centocor-CNTO148ART3002- Phase IIIb-Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in RA Patients who have Inadequate Disease Control Despite Treatment with Etanercept or Adalimumab.

WA19924- Phase IV-A Multi-center, Randomized, Blinded, Parallel-group Study of the Reduction of Signs and Symptoms during Monotherapy Treatment with Tocilizimab 8 mg/kg intravenously versus Adalimumab 40 mg Subcutaneously in Patients with RA.

IM101-226- A Phase IIIB Randomized, Active-controlled Trial to Evaluate the Efficacy and Safety of Abetacept SC in Combination with Methotrexate in Inducing Clinical Remission Compared to Methotrexate Monotherapy in Adults with very early RA.

Oskira-2- A Phase III, Multi-center, Randomized, Doyle-blind, Placebo-controlled, Parallel Group Study of Two Dosing Regimens of Fostamatnib Disodium in RA Patients with Inadequate Response to DMARDs

Oskira III, Multicenter, randomized, Double-blind, Placbo Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatnib Disodium in RA Patients with an Inadequate Response to a TNF-alpha Antagonist.

UCB RA0056- A Randomized, Double-blind, Plcebo-controlled, Dose-ranging Study with an active Comparator to Evaluate the Efficacy and Safety od CDP 6038 Administered SC for 12 Weeks to Subjects with Active RA having Previously TNF alpha blocker Therapy

UCB RA0064–A Phase IV, Multicenter, Randomized, 52-Week Studt to Evaluate the Routine Assessment of Patient Index Data (RAPID) Compared to the Clinical Disease Activity Index (CDAI) to Prospectively Predict Treatment Decision at Week 12 in Subjects with Moderate to Severe RA Receiving Certolizumab Pegol.

Contact this candidate